Zura Bio names new CEO; shares rise

Zura Bio

21/01/2026 15:38

** Shares of drug developer Zura Bio ZURA.O rise 9.18% to $5.47 in early trading

**  Co appoints Sandeep Kulkarni, a director on Zura's board, as CEO, replacing Robert Lisicki

** Kulkarni earlier co-founded Tourmaline Bio, later bought by Novartis NOVN.S

** Outgoing CEO Lisicki had proceeded on medical leave in October, with Kim Davis taking on the role in the interim

** Co's lead drug tibulizumab is in mid-stage tests for hidradenitis suppurativa and systemic sclerosis, both long‑lasting autoimmune conditions, per co

** Co says key trial readouts expected within 18 months

** Shares up ~110% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))